Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1)
Stephen A. Harrison, Carole Thang, Sébastien Bolze, Sheila H. DeWitt, Sophie Hallakou‐Bozec, Julie Dubourg, Pierre Bédossa, Kenneth Cusi, Vlad Ratziu, Jean‐Marie Grouin, David E. Moller, Pascale Fouqueray
Topics & Concepts
PlaceboTolerabilityPioglitazoneMedicineInternal medicineClinical endpointGastroenterologyAdiponectinSteatosisFatty liverFibrosisEndocrinologyRandomized controlled trialAdverse effectInsulinInsulin resistanceType 2 diabetesDiabetes mellitusPathologyDiseaseAlternative medicineLiver Disease Diagnosis and TreatmentLiver physiology and pathologyPeroxisome Proliferator-Activated Receptors